Meningitis Diagnostic Testing Market Share Analysis, Demand, Growth, Trends, Competitive Landscape and Market Forecast 2023-2030

Meningitis Diagnostic Testing Market is segmented By Infection Type(Bacterial, Viral and Fungal), By Diagnosis Type(Latex Agglutination Tests, PCR Assay, Lateral Flow Assay, ELISA Tests, Culture Test and Others), By End-user(Hospitals, Diagnostic Laboratories, Clinics and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Meningitis Diagnostic Testing Market Overview

[180 Pages Report] The Meningitis Diagnostic Testing Market is estimated to reach at a CAGR of 3.7% % during the forecast period (2023-2030). Meningitis is an infection identified by the inflammation of the meninges. The meninges are the three layers of protective tissue: dura mater, arachnoid mater, and pia mater surrounding the neuraxis. Meningitis can be diagnosed by performing blood tests to check for bacteria or viruses that can cause the disease.

Meningitis Diagnostic Testing Market Summary and Scope

Meningitis Diagnostic Testing Market Dynamics and Trends

Meningitis diagnosis at the point of care in a low-resource setting is expected to drive market growth.

Infections of the central nervous system (CNS) are life-threatening conditions affecting thousands of children worldwide, resulting in significant morbidity and mortality and contributing to the current burden of disease in low-income countries. In most African countries, the etiology of CNS infections among children is often unknown due to the lack of advanced laboratory tests. Although different infective agents can cause CNS infections, such as bacteria, viruses, and parasites, the symptoms of the infection, such as fever, are similar. The common symptoms of CNS infection make it difficult to distinguish between different causes of infection clinically, posing challenges to clinical fever case management. The Pediatric Infection-Point-of-Care (PI-POC) trial investigates novel methods to improve and strengthen the differential diagnostics of suspected childhood CNS infections in low-income health systems such as those in Southwestern Uganda. The current gold-standard laboratory methods to confirm suspected cases of CNS infection are bacterial culture and PCR analyses of cerebrospinal fluid (CSF) and blood. The research officials have developed protein-, immuno-, and DNA-based platforms amenable for the POC multiplex format. Moreover, paper-based POC tools offer a superior advantage in terms of costs and simplicity of use and logistics, as they are easy to transport, store, and ultimately dispose of safely via incineration. Therefore there has been an increase in new technologies for diagnosing meningitis in low-income countries which is expected to drive market growth.

Restraint:

Lack of diagnostic laboratory infrastructure in developing countries, and shortage of skilled people for meningitis diagnosis are some of the factors likely to hamper the market growth during the forecast period.

COVID-19 Impact Analysis on Meningitis Diagnostic Testing Market

The pandemic caused by the SARS-CoV-2 virus led to a near-worldwide lockdown had a disastrous impact on meningitis diagnostic testing; with the spread of the COVID-19 pandemic, reports of bacterial coinfection in sick patients have become more frequent. Its manifestation can be considered as a direct impact of the virus on target organs and systems in humans. There have been reports of some patients developing meningitis due to various bacteria, such as N. meningitides. Diagnosing and treating patients with a highly contagious infection, such as COVID-19, is not easy. Moreover, the differential diagnosis of bacterial and viral meningitis remains an important and unsolved clinical problem, especially in the initial hours of hospitalization, before receiving lumbal puncture results. Classical clinical diagnostic signs have limited value in establishing the diagnosis of meningitis. Timely and rapid diagnosis and treatment of bacterial meningitis in the view of a proven COVID-19 infection require a variety of biological tests and a multidisciplinary approach. In the early stages of acute bacterial and viral meningitis, the signs and symptoms are often nonspecific, and it is not always possible to make a differential diagnosis.

Additionally,  the COVID-19 pandemic continues to unfold, and medical device companies find it difficult to make informed decisions about their products, supply chains, and regulatory obligations amid uncertainty. Medical device professionals have the unenviable task of asking for a pause amid the panic. The pandemic is not likely to have long-term effects on end-users primary growth in meningitis diagnostic testing.

Meningitis Diagnostic Testing Market Segmentation Analysis

PCR Assay segment is expected to hold the largest market share in the meningitis diagnostic testing market

The PCR assay segment is estimated for the largest market share in 2020. The growth of the segment is due to its highly precise and accurate test results in a short time compared to conventional tests, with the highest sensitivity rate. For instance, bacterial meningitis is a major global cause of morbidity and mortality. Rapid identification of the aetiological agent of meningitis is essential for clinical and public health management. Disease prevention is given the wide range of pathogens that cause the clinical syndrome and the availability of vaccines that protect against some, but not all, of these. Since microbiological culture is complex, slow, and often impacted by prior antimicrobial treatment of the patient, molecular diagnostic assays have been developed for bacterial detection. Molecular tools including the polymerase chain reaction (PCR), real-time PCR (rtPCR), qualitative or quantitative PCR (qPCR), and loop-mediated isothermal amplification assays (LAMP) have the potential to overcome many of the limitations of culture-based approaches, as they target bacterial DNA and are not compelled by the presence of cultivable organisms. These molecular tools are now the methods of choice for many laboratories and have improved public health measures. They involve standard, generic laboratory techniques that allow multiple pathogens to be rapidly detected. Indeed, the World Health Organisation (WHO) recommends using rtPCR in the testing of pneumococcus, meningococcus, and Hib from suspected cases of meningitis. The first molecular methods to be developed were PCR assays that detect a single pathogen. Still, these have been largely succeeded by multiplex PCR assays (simultaneous testing of multiple targets) such as rtPCR assays, which reduce time and consumable costs. Therefore, its highly precise and accurate test results have increased the demand for the PCR Assay test in a short time.

Meningitis Diagnostic Testing Market Geographical Share

North America region holds the largest market share in the global meningitis diagnostic testing market

North America accounted for the largest revenue share in 2020. The early adoption of diagnostic technologies, the increased numbers of diagnostic centers, increasing new diagnostic techniques in the region are all factors that are expected to boost the region's growth in the forecast period. For instance, infectious meningitis is caused by numerous pathogens and may be life-threatening. The classic symptoms of meningitis are fever, neck stiffness and headaches, although these features are not present uniformly. Broadly, the most common causes of infectious meningitis are viral, bacterial, mycobacterial and fungal. In the USA, meningitis accounts for more than 72,000 hospitalizations, with a total expenditure of 1.2 billion dollars annually. Much infectious meningitis carries high mortality rates and long-term complications, including neurologic deficits and cognitive impairment. More rapid techniques such as the cryptococcal lateral flow assay (IMMY), GeneXpert MTB/Rif Ultra (Cepheid) and FilmArray multiplex-PCR (Biofire) are three examples that have drastically changed meningitis diagnostics. Therefore, the increase in new diagnostic techniques has increased the demand for these techniques to diagnose the early detection of meningitis. Thus, the region is expected to hold the largest market share in the forecast period from the above statements.

Meningitis Diagnostic Testing Companies and Competitive Landscape

Major key players in the meningitis diagnostic testing market are Thermo Fisher Scientific Inc, Seegene Inc., BioFire Diagnostics LLC (BioMérieux), Teco Diagnostics, ELITech Group, Transasia Bio-Medicals Ltd., Lepu Medical Technology, Eurolyser Diagnostica and Gold Standard Diagnostics. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the meningitis diagnostic testing market globally. For instance, on January 19, 2021, Thermo Fisher Scientific has entered into a definitive agreement to acquire Mesa Biotech, Inc., a privately held molecular diagnostic company, for approximately $450 million in cash.

Thermo Fisher Scientific Inc:

Overview:

Thermo Fisher Scientific is an American company incorporated in 1956 and is based in Waltham, Massachusetts. The company offers life sciences solutions, analytical instruments, speciality diagnostics, and laboratory products and services worldwide. Moreover, the global team has more than 90,000 colleagues who deliver an unrivalled combination of innovative technologies, purchasing convenience and pharmaceutical services through industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Product Portfolio:

• Wellcogen Bacterial Antigen Rapid Latex Agglutination Test, Bacterial Meningitis: The WellcogenTM Bacterial Antigen Kit includes a set of rapid latex tests for detecting antigen from Streptococcus group B, Haemophilus influenza type b, Streptococcus pneumoniae (pneumococcus), Neisseria meningitides (meningococcus) groups A, B, C, Y, or W135 and Escherichia coli K1 in cerebrospinal fluid. The kit also tests other body fluids or blood culture supernatants for most of these antigens and plate cultures for N. meningitides group B or Escherichia coli K1.